TuHURA Biosciences (NASDAQ:HURA) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of TuHURA Biosciences (NASDAQ:HURA) from a hold rating to a sell rating in a report released on Sunday morning.

HURA has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Wednesday, October 8th. Maxim Group lowered their price objective on TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $10.33.

TuHURA Biosciences Stock Performance

Shares of TuHURA Biosciences stock opened at $1.03 on Friday. The firm has a 50-day moving average of $2.14 and a 200-day moving average of $2.46. TuHURA Biosciences has a 52-week low of $0.97 and a 52-week high of $5.61. The stock has a market cap of $52.54 million, a PE ratio of -2.05 and a beta of -0.03.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01.

Institutional Investors Weigh In On TuHURA Biosciences

A number of large investors have recently modified their holdings of HURA. Invst LLC bought a new stake in shares of TuHURA Biosciences during the 1st quarter worth $61,000. PFG Investments LLC bought a new position in TuHURA Biosciences in the third quarter valued at about $58,000. SG Americas Securities LLC acquired a new position in TuHURA Biosciences during the third quarter worth about $41,000. Apollon Wealth Management LLC lifted its holdings in shares of TuHURA Biosciences by 15.8% in the third quarter. Apollon Wealth Management LLC now owns 133,526 shares of the company’s stock worth $331,000 after acquiring an additional 18,252 shares during the last quarter. Finally, Brighton Jones LLC acquired a new stake in shares of TuHURA Biosciences in the 3rd quarter valued at approximately $69,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.